Patents by Inventor Hans-Peter Buchstaller

Hans-Peter Buchstaller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8993564
    Abstract: Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed treatment of tumours.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller
  • Publication number: 20150057264
    Abstract: Compounds of the formula I in which R1, X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 26, 2015
    Applicant: Merck Patent GmbH
    Inventors: Dieter Dorsch, Hans-Peter Buchstaller, Gerard Moinet, Ansgar Wegener
  • Publication number: 20150025071
    Abstract: Compounds of the formula I in which U, V and W have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: January 14, 2013
    Publication date: January 22, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Christina Esdar, Birgitta Leuthner
  • Publication number: 20140371215
    Abstract: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: August 13, 2014
    Publication date: December 18, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Timo HEINRICH, Margarita WUCHERER-PLIETKER, Hans-Peter BUCHSTALLER
  • Patent number: 8906930
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R4 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: December 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans Michael Eggenweiler, Christian Sirrenberg, Hans Peter Buchstaller
  • Patent number: 8895575
    Abstract: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: November 25, 2014
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller
  • Patent number: 8895559
    Abstract: A variety of specific compounds within the scope of formula I which are useful as PI3K inhibitors and can be employed for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours, and pharmaceutical compositions and kits containing said specific compounds.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: November 25, 2014
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Ulrich Emde, Hans-Peter Buchstaller, Christina Esdar, Oliver Poeschke
  • Publication number: 20140275072
    Abstract: The invention relates to compounds of the formula (I) in which R1, L and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into a salt thereof.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 18, 2014
    Applicant: Merck Patent GmbH
    Inventors: Werner Mederski, Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller
  • Patent number: 8816070
    Abstract: 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: August 26, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans Michael Eggenweiler, Michael Wolf, Hans Peter Buchstaller, Christian Sirrenberg
  • Patent number: 8802866
    Abstract: Compounds of the formula (I), in which X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, R10 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumors.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Patent GmbH
    Inventors: Ulrich Emde, Hans Peter Buchstaller, Markus Klein, Christina Esdar, Joerg Bomke
  • Patent number: 8791129
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R43 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: July 29, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • Publication number: 20140187551
    Abstract: Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed treatment of tumours.
    Type: Application
    Filed: May 29, 2012
    Publication date: July 3, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller
  • Patent number: 8741896
    Abstract: Compounds of the formula (I), in which X, R1 and R2 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumors.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: June 3, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans Peter Buchstaller, Ulrich Emde, Markus Klein, Christina Esdar, Joerg Bomke
  • Patent number: 8722903
    Abstract: Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim (1), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: May 13, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Hans-Michael Eggenweiler, Michael Wolf, Christian Sirrenberg
  • Publication number: 20140100221
    Abstract: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 10, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Timo HEINRICH, Margarita WUCHERER-PLIETKER, Hans-Peter BUCHSTALLER
  • Patent number: 8664236
    Abstract: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: March 4, 2014
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller
  • Patent number: 8546565
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R5 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Patent Gesellschaft
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • Publication number: 20130245355
    Abstract: Compounds of the formula I in which Q, R1, R2, R3 and R4 have the meanings indicated in Claim 1, are PDK1 inhibitors and can be employed for the treatment of tumours.
    Type: Application
    Filed: November 17, 2011
    Publication date: September 19, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Margarita Wucherer-Plietker, Timo Heinrich
  • Publication number: 20130231519
    Abstract: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: October 12, 2011
    Publication date: September 5, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller
  • Publication number: 20130217670
    Abstract: Compounds of the formula I in which R, R1 and R2 have the meanings indicated in Claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours.
    Type: Application
    Filed: September 22, 2011
    Publication date: August 22, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Markus Klein, Ulrich Emde, Hans-Peter Buchstaller, Christina Esdar, Oliver Poeschke